Moleculin Biotech, Inc. Share Price & Technical Analysis
MBRX · $2.39 (0.00%)
Healthcare / Biotechnology
$2.39
0.00%
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 por…
Price chart
Seasonality
May has 0 positive and 5 negative years (last 5 years shown)
-8% return in May, -13% avg return in past 3 year May month.
-9% return in 2026, -93% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 30% | -44% | 0% | 13% | -8% | – | – | – | – | – | – | – | -9% |
| 25 | -13% | -14% | -22% | 6% | -17% | -65% | 112% | -35% | 35% | -14% | -40% | -49% | -116% |
| 24 | -41% | 25% | -37% | -13% | -5% | -24% | -11% | -19% | 12% | -8% | 8% | -39% | -154% |
| 23 | 16% | -6% | -21% | -20% | -17% | -9% | 7% | -12% | -27% | 8% | 30% | 43% | -7% |
| 22 | -17% | -9% | 28% | -12% | -9% | -5% | 19% | -10% | -29% | -5% | 41% | -25% | -32% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Uptrend
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$13.02M
P/E ratio
—
52W high
$24.00
52W low
$1.79
Volume
11,678
Beta
1.74
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Moleculin Biotech, Inc. share price today?
- Moleculin Biotech, Inc. (MBRX) last traded around $2.39 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does MBRX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for MBRX. Download the app for real-time alerts.
- How can I analyze Moleculin Biotech, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.